ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Consistency over intensity: atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in ACS patients: a comparative study of efficacy, tolerability, and cardiovascular outcomes.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite guideline recommendations for high-intensity statins in acute coronary syndrome (ACS) patients, real-world data show underutilization and suboptimal low-density lipoprotein cholesterol (LDL-C) target achievement. The statin-associated muscle symptoms (SAMS) is often a major limitation to drug compliance and hence to achieving LDL-C targets.
methodsIn this prospective, open label, randomized controlled trial, 502 ACS patients were randomized 1:1 to atorvastatin 80 mg monotherapy (Group A) versus atorvastatin 40 mg plus ezetimibe 10 mg (Group AE), aiming to compare the efficacy, safety, and tolerability of both treatment arms. Lipid profiles, safety, and clinical outcomes were assessed at baseline, 6 weeks, 6 months, and 12 months. The primary endpoints were LDL-C reduction, SAMS, and major adverse cardiovascular events (MACE).
resultsThe mean age of participants was 56 ± 10 years, with 83% males, 55% diabetics, and 77% hypertensives. Baseline characteristics were comparable between groups. Group AE demonstrated superior LDL-C reduction at all timepoints (p < 0.01), with greater improvements in high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG). Group AE also showed significantly fewer events of treatment discontinuation (DC) or dose reduction (DR) (OR 0.50; 95% CI 0.31-0.81) and a 25.7% relative risk reduction (RRR) in the composite of MACE compared to Group A. SAMS and non-limiting muscle aches were significantly lower in Group AE (p < 0.05), with no cases of rhabdomyolysis reported. Subgroup analysis confirmed consistent benefits of Group AE in both diabetic and non-diabetic patients.
conclusionAtorvastatin 40 mg plus ezetimibe 10 mg demonstrated superior LDL-C reduction, improved tolerability, and fewer MACE compared to atorvastatin 80 mg monotherapy in ACS patients. These findings support the use of combination therapy as a viable starting alternative to atorvastatin 80 mg monotherapy following ACS, particularly in patients likely to have statin intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.